Abstract:Context:The liver is both the largest metabolic and the largest immune organ and is closely related to the mechanisms of disease development. Clarifying the immune environment of the NAFLD liver to determine its interactions with biomarkers would be beneficial in exploring the mechanisms of disease development. Objective:The study aimed to identify biomarkers and immune cells associated with nonalcoholic fatty liver disease (NAFLD) and to analyze the correlation between key genes and immune cells in NAFLD, to improve the understanding of the mechanisms underlying NAFLD and provide potential therapeutic targets. Design:The research team performed a genetic study. Setting:The study took place at Qingdao, Shandong Province, China. Outcome Measures:The research team: (1) obtained the NAFLD-related datasets GSE63067, GSE48452, and GSE89632 from the Gene Expression Omnibus (GEO) database; (2) analyzed immune-cell infiltrates using single-sample gene set enrichment analysis (ssGSEA) to determine the hub immune cells; (3) selected the differentially expressed genes (DEGs) between the NAFLD and normal samples and screened them to identify the hub genes; (4) evaluated the efficiency of the hub genes using receiver operating characteristic (ROC) curves; and (5) analyzed the correlations between hub genes and immune cells. Results:The research team: (1) found 28 differential immune cells; (2) identified monocytes as the hub immune cells; (3) identified 55 DEGs; (4) comparing the top 10 genes, identified five hub genes: S100 calcium binding proteins A12 (S100A12), S100A9, S100A8, selectin L (SELL), and sex hormone binding globulin (SHBG); (5) for all five, the area under the ROC curve (AUC) was greater than 0.6-training set: AUCSA00A12 = 0.699, AUCSELL = 0.743, AUCS100A9 = 0.735, AUCSHBG = 0.752, and AUCS100A8 = 0.703; and validation set: AUCSA00A12 = 0.852, AUCSELL = 0.905, AUCS100A9 = 0.819, AUCSHBG = 0.830, and AUCS100A8 = 0.822; (6) negatively correlated SHBG with immune cells (P > .05, r=-0.09); and (7) positively correlated S100A12, S100A9, S100A8, and SELL with immune cells-rS100A8 = 0.40, rS100A9 = 0.50, rS100A12 = 0.38, and rSELL = 0.42, respectively. Conclusions:Based on bioinformatic analyses, the progression of NAFLD may involve monocytes through promotion of liver inflammation. The hub genes S100A12, S100A9, S100A8, SELL, and SHBG are potential biomarkers that may be useful as diagnostic tools or therapeutic targets for NAFLD.

Combined with multiplex and network analysis to reveal the key genes and mechanisms of nonalcoholic fatty liver disease

Identification of Genes and Key Pathways Underlying the Pathophysiological Association Between Nonalcoholic Fatty Liver Disease and Atrial Fibrillation

Identification of Key Pathways and Genes in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis

Identification of Key Genes and Pathways in Mild and Severe Nonalcoholic Fatty Liver Disease by Integrative Analysis.

Proteomic analysis to identify differentially expressed proteins between subjects with metabolic healthy obesity and non-alcoholic fatty liver disease.

Multi-omics analysis of the biological mechanism of the pathogenesis of non-alcoholic fatty liver disease

Identification of metabolic biomarkers associated with nonalcoholic fatty liver disease

Identification of Hub Genes and Key Pathways of Dietary Advanced Glycation End Products-Induced Non-Alcoholic Fatty Liver Disease by Bioinformatics Analysis and Animal Experiments

Gene-metabolite Network Analysis in Different Nonalcoholic Fatty Liver Disease Phenotypes

Functional Proteomic Analysis of Nonalcoholic Fatty Liver Disease in Rat Models: Enoyl-coenzyme a Hydratase Down-Regulation Exacerbates Hepatic Steatosis

Identification of key target genes and pathway analysis in nonalcoholic fatty liver disease via integrated bioinformatics analysis

Identification of common signature genes and pathways underlying the pathogenesis association between nonalcoholic fatty liver disease and heart failure

Target genes associated with lipid and glucose metabolism in non-alcoholic fatty liver disease

Transcriptomic profiling of hepatic tissues for drug metabolism genes in nonalcoholic fatty liver disease: A study of human and animals

Integrating Multi-Omics Reveals Crucial Biomarkers in Non-Alcoholic Fatty Liver Disease

Functional Investigation and Two-Sample Mendelian Randomization Study of Non-Alcoholic Fatty Liver Disease Hub Genes Obtained by WGCNA

A Comprehensive Bioinformatics Analysis on Multiple Gene Expression Omnibus Datasets of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

Identification and validation of INHBE and P4HA1 as hub genes in non-alcoholic fatty liver disease

Key genes associated with non-alcoholic fatty liver disease and hepatocellular carcinoma with metabolic risk factors

Integrated analysis of potential gene crosstalk between non-alcoholic fatty liver disease and diabetic nephropathy

Bioinformatic Analysis of Key Biomarkers and Infiltrating Immune Cells in Nonalcoholic Fatty Liver Disease.